Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Biodistribution and dosimetry of TRODAT-1: A technetium-99m tropane for imaging dopamine transporters
Autore:
Mozley, PD; Stubbs, JB; Plossl, K; Dresel, SH; Barraclough, ED; Alavi, A; Araujo, LI; Kung, HF;
Indirizzi:
Univ Penn, Philadelphia, PA 19104 USA Univ Penn Philadelphia PA USA 19104Univ Penn, Philadelphia, PA 19104 USA Internal Dosimetry Syst Oak Ridge, Oak Ridge, TN USA Internal Dosimetry Syst Oak Ridge Oak Ridge TN USA ge, Oak Ridge, TN USA
Titolo Testata:
JOURNAL OF NUCLEAR MEDICINE
fascicolo: 12, volume: 39, anno: 1998,
pagine: 2069 - 2076
SICI:
0161-5505(199812)39:12<2069:BADOTA>2.0.ZU;2-B
Fonte:
ISI
Lingua:
ENG
Soggetto:
POSITRON EMISSION TOMOGRAPHY; COCAINE RECOGNITION SITES; MONOAMINE REUPTAKE SITES; BETA-CIT; COMPUTED-TOMOGRAPHY; SEROTONIN TRANSPORTERS; PARKINSONS-DISEASE; LIGAND-BINDING; PRIMATE BRAIN; I-125 RTI-55;
Keywords:
technetium-99m; TRODAT-1; brain; computed tomography;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
72
Recensione:
Indirizzi per estratti:
Indirizzo: Mozley, PD HospSAniv Penn, 3400 Spruce St,110-D Donnner Bldg, Philadelphia, PA 19104 U Hosp Univ Penn 3400 Spruce St,110-D Donnner Bldg Philadelphia PA USA 19104
Citazione:
P.D. Mozley et al., "Biodistribution and dosimetry of TRODAT-1: A technetium-99m tropane for imaging dopamine transporters", J NUCL MED, 39(12), 1998, pp. 2069-2076

Abstract

Technetium-99m TRODAT-1 is an analog of cocaine that selectively binds thepresynaptic dopamine transporters. The primary purpose of this study was to measure its whole-body biokinetics and radiation dosimetry in healthy human volunteers. The study was conducted within a regulatory framework that required its pharmacological safety to be assessed simultaneously. Methods: The sample included 4 men and 6 women ranging in age from 22-54 yr. An average of 20 whole-body scans were acquired sequentially on a dual-head camerafor up to 46 hr after the intravenous administration of 370 +/- 16 MBq (10.0 +/- 0.42 mCi) Tc-99m TRODAT. The renal excretion fractions were measuredfrom 12-24 discrete urine specimens. The fraction of the administered dosein 17 regions of interest and each urine specimen was quantified from the attenuation and background corrected geometric mean counts in conjugate views. Multiexponential functions were iteratively fit to each time-activity curve using a nonlinear, least squares regression algorithm. These curves were numerically integrated to yield source organ residence times. Gender-specific radiation doses were then estimated with the Medical Internal Radiation Dose technique for each subject individually before any results were averaged. Results: There were no pharmacological effects of the radiotracer onany of the subjects. The early planar images showed differentially increased activity in the nose, pudendum and stomach. SPECT images demonstrated that the radiopharmaceutical localized in the basal ganglia in a distributionthat was consistent with selective transporter binding. Image analysis showed that the kidneys excreted between 20% and 32% of the injected dose during the first 22-28 hr postadministration, after which no more activity could be recovered in the urine. The dose limiting organ in both men and women was the liver, which received an average of 0.046 mGy/MBq (0.17 rads/mCi, range 0.14-0.22 rad/mCi). In the worst case, which was clearly an overestimation, it would have taken 22.7 mCi to deliver 5 rad to the liver. Conclusion: TRODAT may be a safe and effective radiotracer for imaging dopamine transporters in the brain and the body.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/01/20 alle ore 16:16:43